financetom
Business
financetom
/
Business
/
Former Tesla CEO Eberhard says 'shame' company is cancelling low-cost car plans
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Former Tesla CEO Eberhard says 'shame' company is cancelling low-cost car plans
Apr 8, 2024 11:55 PM

HONG KONG, April 9 (Reuters) - A Tesla Inc ( TSLA )

founder and former chief executive, Martin Eberhard, said on

Tuesday it was a "shame" to hear that the company was scrapping

its low-cost car plans amid fierce competition in China.

Eberhard was speaking at the HSBC Global Investment Summit

in Hong Kong. Reuters reported on Friday that Tesla was

cancelling its long-promised inexpensive car that investors had

been counting on to drive its growth.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Blockmate Investee Hivello Enters AI Partnership with AIxBlock
Blockmate Investee Hivello Enters AI Partnership with AIxBlock
Jan 24, 2025
11:18 AM EST, 01/24/2025 (MT Newswires) -- Blockmate Ventures ( MATEF ) said Friday its investee Hivello Holdings partnered with artificial intelligence development platform AIxBlock to integrate decentralized computing power into AI applications. AIxBlock offers a comprehensive development platform to build, train and deploy AI models that typically have high computing power requirements to function optimally, Blockmate ( MATEF )...
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Novo Nordisk Obesity Drug Achieves Up to 22% Weight Loss in Clinical Trial
Jan 24, 2025
11:16 AM EST, 01/24/2025 (MT Newswires) -- Novo Nordisk's ( NVO ) said Friday that its investigative weight loss drug, amycretin, led to a body weight reduction of up to 22% in an early-stage trial. The maker of obesity drug Wegovy and diabetes treatment Ozempic said its phase 1b/2a trial covered 125 overweight people. The trial involved three different once-weekly...
Texas Instruments' Gross Margin Performance to Trail Peers, Morgan Stanley Says
Texas Instruments' Gross Margin Performance to Trail Peers, Morgan Stanley Says
Jan 24, 2025
11:18 AM EST, 01/24/2025 (MT Newswires) -- Texas Instruments' ( TXN ) gross margins are expected to lag behind industry peers until 2026, while free cash flow benefits are seen somewhat overstated, Morgan Stanley said Friday in a note. The company's gross margins have declined significantly, from above 70% to the mid-50% range, the firm said, following the release of...
Union Pacific Delivered 'Comfortable' Q4 Headline Beat But Remains 'Show-Me Story' in the Near Term, Morgan Stanley Says
Union Pacific Delivered 'Comfortable' Q4 Headline Beat But Remains 'Show-Me Story' in the Near Term, Morgan Stanley Says
Jan 24, 2025
11:17 AM EST, 01/24/2025 (MT Newswires) -- Union Pacific ( UNP ) delivered a decent headline beat with its Q4 results helped by one time-ish cost items, Morgan Stanley said in a note to clients emailed Friday. The railroad company also provided somewhat vague guidance, the investment firm said, adding that Union Pacific ( UNP ), like its peers in...
Copyright 2023-2026 - www.financetom.com All Rights Reserved